Nektar Therapeutics Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
137
- Stock Symbol
-
NKTR
- Investments
-
3
- Share Price
-
$1.25
- (As of Thursday Closing)
Nektar Therapeutics General Information
Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Contact Information
Website
www.nektar.comCorporate Office
- 455 Mission Bay Boulevard South
- San Francisco, CA 94158
- United States
Corporate Office
- 455 Mission Bay Boulevard South
- San Francisco, CA 94158
- United States
Nektar Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.25 | $1.25 | $0.41 - $1.93 | $230M | 184M | 1.56M | -$0.90 |
Nektar Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 53,024 | (143,585) | 13,043 | 1,718,745 |
| Revenue | 93,157 | 90,122 | 92,055 | 101,907 |
| EBITDA | (163,545) | (262,116) | (329,825) | (464,552) |
| Net Income | (177,081) | (276,056) | (368,198) | (523,837) |
| Total Assets | 343,334 | 398,033 | 710,600 | 1,117,189 |
| Total Debt | 112,100 | 117,776 | 131,496 | 143,177 |
Nektar Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nektar Therapeutics Comparisons
Industry
Financing
Details
000000
000000
Nektar Therapeutics Competitors (133)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seagen | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 | 00.000 |
| Incyte | Formerly VC-backed | Wilmington, DE | 0000 | 00000 | 00000000000 | 00000 |
| Exelixis | Formerly VC-backed | Alameda, CA | 0000 | 00000 | 000000&0 | |
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000000 00 | 00000 |
| BeiGene | Formerly PE-Backed | Cambridge, MA | 0000 | 00.000 | 000000&0 | 00.000 |
Nektar Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nektar Therapeutics Patents
Nektar Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022414070-A1 | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions | Pending | 14-Dec-2021 | 00000000000 | |
| CA-3239501-A1 | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions | Pending | 14-Dec-2021 | 00000000000 | |
| EP-4370536-A2 | Polymer engineered forms of interferon-gamma and methods of use | Pending | 12-Jul-2021 | 000000000 | |
| EP-4355371-A1 | Histidine-selective polymer reagents | Pending | 17-Jun-2021 | 000000000 | |
| US-20240299561-A1 | Histidine-selective polymer reagents | Pending | 17-Jun-2021 | A61K47/60 |
Nektar Therapeutics Executive Team (31)
| Name | Title | Board Seat |
|---|---|---|
| Howard Robin | Chief Executive Officer, President & Board Member | |
| Sandra Gardiner | Chief Financial Officer | |
| Mark Wilson JD | Senior Vice President & Chief Legal Officer, Legal | |
| Vivian Wu | Director, Investor Relations & Corporate Affairs | |
| John Northcott | Executive & Senior Vice President |
Nektar Therapeutics Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Diana Brainard MD | Self | Board Member | 000 0000 |
| Howard Robin | Nektar Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 |
| Jeffrey Ajer | Self | Board Member | 000 0000 |
| Lutz Lingnau | Self | Board Member | 000 0000 |
| Myriam Curet MD | Self | Board Member | 000 0000 |
Nektar Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Nektar Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Nektar Therapeutics Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pearl Therapeutics | 01-Jul-2008 | 00000 0000 | 000.00 | Therapeutic Devices | |
| Aerogen | 20-Oct-2005 | 0000000000 | 000.00 | Drug Delivery | |
| Shearwater | 01-Jun-2001 | Merger/Acquisition | 00000 | Specialty Chemicals |
Nektar Therapeutics ESG
Risk Overview
Risk Rating
Updated September, 07, 2023
37.84 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,842
Rank
Percentile
Pharmaceuticals
Industry
00 of 898
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 428
Rank
Percentile
Nektar Therapeutics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pearl Therapeutics | 01-Jul-2008 | 00000 00000 | 000.00 | Completed |
|
Nektar Therapeutics FAQs
-
When was Nektar Therapeutics founded?
Nektar Therapeutics was founded in 1990.
-
Who is the CEO of Nektar Therapeutics?
Howard Robin is the CEO of Nektar Therapeutics.
-
Where is Nektar Therapeutics headquartered?
Nektar Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Nektar Therapeutics?
Nektar Therapeutics has 137 total employees.
-
What industry is Nektar Therapeutics in?
Nektar Therapeutics’s primary industry is Biotechnology.
-
Is Nektar Therapeutics a private or public company?
Nektar Therapeutics is a Public company.
-
What is Nektar Therapeutics’s stock symbol?
The ticker symbol for Nektar Therapeutics is NKTR.
-
What is the current stock price of Nektar Therapeutics?
As of 12-Sep-2024 the stock price of Nektar Therapeutics is $1.25.
-
What is the current market cap of Nektar Therapeutics?
The current market capitalization of Nektar Therapeutics is $230M.
-
What is Nektar Therapeutics’s current revenue?
The trailing twelve month revenue for Nektar Therapeutics is $93.2M.
-
Who are Nektar Therapeutics’s competitors?
Seagen, Incyte, Exelixis, Coherus Biosciences, and BeiGene are some of the 133 competitors of Nektar Therapeutics.
-
What is Nektar Therapeutics’s annual earnings per share (EPS)?
Nektar Therapeutics’s EPS for 12 months was -$0.90.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
